Immix Biopharma, Inc. IMMX Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average exercise price beginning balance1.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average exercise price beginning balance1?
- Immix Biopharma, Inc. (IMMX) reported sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average exercise price beginning balance1 of $2.33 in Q1 2026.
- How has Immix Biopharma, Inc.'s sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average exercise price beginning balance1 changed year-over-year?
- Immix Biopharma, Inc.'s sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average exercise price beginning balance1 increased by 15.3% year-over-year, from $2.02 to $2.33.
- What is the long-term trend for Immix Biopharma, Inc.'s sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average exercise price beginning balance1?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s sharebased compensation shares authorized under stock option plans exercise price range outstanding options weighted average exercise price beginning balance1 has grown at a 9.3% compound annual growth rate (CAGR), from $1.54 to $2.2.